Mr. Clark is a Partner in Palladium Equity Partners, a private equity firm based in New York, NY. Mr. Clark serves on the Board of Directors of several Palladium portfolio companies as well as the firm’s investment and management committees. He currently leads the firm’s Industrial team. Previously he was a Vice President at Windjammer Capital Investors where he sourced, analyzed and structured investments in a range of industries. Before joining Windjammer, Mr. Clark was an Associate at Genstar Capital, a San Francisco based private equity investment firm. Prior to Genstar, Mr. Clark was an investment banking analyst at Deutsche Banc Alex Brown. Mr. Clark received his B.A. from Middlebury College, where he double majored in political science and economics, and an M.B.A. from Columbia Business School.
Mr. DeWahl joined Ischemix in January 2013 as President and Chief Executive Officer. He was previously Vice President of Corporate Development for Helix Therapeutics, Inc., a private company utilizing DNA repair technology licensed from Yale University to treat patients with genetically-based diseases. Mr. DeWahl is also a co-founder of Life Science Pharmaceuticals, Inc., which is developing novel therapeutics to treat cancer, diabetes and other serious illnesses based on IP licensed from The Ludwig Institute for Cancer Research, Memorial Sloan Kettering, Dana Farber and other major academic research institutions.
Prior to his experience in the biopharmaceutical industry, Mr. DeWahl was an investment banker focused on the health care and life sciences industry for over 25 years, including positions as a Managing Director at Prudential Securities, Oppenheimer and Co., Vector Securities and Life Science Group. Mr. DeWahl has successfully raised capital and/or advised on corporate partnerships for numerous companies with biopharmaceutical and other life science products currently on the market, including Tarceva® (Roche/Genentech), Byetta® (Bristol-Myers/Amylin), Synvisc® (Sanofi/Genzyme), Adagen® (Enzon) and WinRho® (Cangene).
Mr. DeWahl received his BA in economics from the University of Wisconsin and his MBA in finance from Columbia University.
Dr. Beeuwkes joined Ischemix in 2002 as a Director and was appointed President/CEO in 2005. Dr. Beeuwkes began his career working with Nobelist Bernard Lown on "cardioversion", the electrical correction of cardiac arrhythmia. From 1970 to 1982, Dr. Beeuwkes held a faculty position at Harvard Medical School. His work centered on the microcirculation of the kidney and heart, and resulted in more than 80 publications, including four chapters in renal textbooks and three award-winning kidney-focused educational films. With A. Clifford Barger, he discovered the association of coronary vasa vasorum with atherosclerotic plaque. This work is widely cited in myocardial infarction literature. In 1982, Dr. Beeuwkes co-founded Braintree Laboratories, Inc., a privately held pharmaceutical company which pioneered products for colonoscopy. From 1982-1987, he served as Director of Renal and Cardiovascular Pharmacology at Smith Kline and French Laboratories and Director of Strategic Planning for SmithKline Worldwide R&D. He holds nine U.S. patents. Dr. Beeuwkes earned his B.S. from The Massachusetts Institute of Technology and his Ph.D. from Harvard University.
Dr. Milner is Chairman and co-founder of Armetheon, a private company conducting a Phase 3 trial of a novel oral anticoagulant. Previously he was CEO of Heart Metabolics, a private company addressing hypertrophic cardio-myopathy. Dr. Milner also co-founded Optivia Biotechnology, a leading transporter biology company as well as ARYx Therapeutics, where he served as CEO and President. Previously he co-founded the cardiovascular company CV Therapeutics. Dr. Milner is a board certified cardiologist, a Fellow of the American College of Cardiology, and co-inventor on 50 patents and author of many original papers. He serves as adjunct clinical faculty at Stanford University and as a board member of the California Life Sciences Association.
Dr. Milner received his medical degree from the University of Liverpool and undertook post-graduate training at Johns Hopkins Hospital and The University of Virginia.
Dr. Shashoua is the son of the late scientific founder, Dr. Victor Shashoua. He is currently in a multi-specialty practice at Harvard Vanguard Medical Associates. Dr. Shashoua began his career in real estate and then studied medicine, receiving his degree from the University of New England in Maine. He trained in Internal Medicine at Roger Williams Medical Center, an affiliate of Boston University Medical School.
